Asunto(s)
Citotoxicidad Celular Dependiente de Anticuerpos , Antígenos CD20/inmunología , Deleción Cromosómica , Cromosomas Humanos Par 17 , Leucemia Linfocítica Crónica de Células B/inmunología , Femenino , Humanos , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Linfocítica Crónica de Células B/terapia , MasculinoRESUMEN
Although anti-CD20 monoclonal antibodies (mAbs) show promise for the treatment of chronic lymphocytic leukemia (CLL), the success of the anti-CD20 mAb rituximab in CLL treatment has been limited. Novel anti-CD20 mAbs with more potent cytotoxic activity have recently been engineered, but so far most have only been tested in vitro with natural killer (NK) cells from healthy donors. Because it is still unclear whether these optimized cytotoxic mAbs will improve NK-cell killing of tumor cells in CLL patients, we characterized the relevant phenotypic and functional features of NK cells from CLL patients in detail. Expression of inhibitory and activating NK-cell receptors and of Fc gamma receptor IIIA (FcγRIIIA) is well preserved in CD16(+)CD56(dim) cytotoxic NK cells from these patients, independently of disease progression. These cells are fully functional following cytokine stimulation. In addition, the FcγRIIIA-optimized LFB-R603 anti-CD20 mAb mediates 100 times greater antibody-dependent cell-mediated cytotoxicity by NK cells from CLL patients and healthy donors than rituximab. Enhanced degranulation against autologous B-CLL cells is observed at lower concentrations of LFB-R603 than rituximab, regardless of CLL prognostic factors. These findings strongly justify further clinical development of anti-CD20 mAbs optimized for FcγR engagement in CLL patients.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Antígeno CD56/análisis , Células Asesinas Naturales/inmunología , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Receptores de IgG/análisis , Adulto , Anciano , Anciano de 80 o más Años , Citotoxicidad Celular Dependiente de Anticuerpos , Femenino , Proteínas Ligadas a GPI/análisis , Humanos , Inmunofenotipificación , Leucemia Linfocítica Crónica de Células B/inmunología , Masculino , Persona de Mediana Edad , RituximabRESUMEN
Sixty-four IgG Rh monoclonal antibodies (Mabs) submitted to the Fourth International Workshop on Monoclonal Antibodies Against Human Red Blood Cells and Related Antigens were characterised and tested in quantitative functional assays at five laboratories. The biological assays measured the ability of anti-D to mediate phagocytosis or extracellular lysis of RBC by IgG Fc receptor (Fc gamma R)-bearing effector cells. Interactions of RBC pre-sensitised with anti-D (EA-IgG) with monocytes in chemiluminescence (CL) assays were found proportional to the amount of IgG anti-D on the RBC. Using antibodies to inhibit Fc gamma RI, Fc gamma RII or Fc gamma RIII, the only receptor utilised in the monocyte CL and ADCC assays for interactions with EA-IgG1 was found to be Fc gamma RI. In these assays, enhanced interactions were promoted by EA-IgG3 and additional Fc gamma receptors may have contributed. IgG2 anti-D was not reactive in these assays and EA-IgG4 promoted weak reactions through Fc gamma RI. A macrophage ADCC assay showed that haemolysis of EA-IgG3 was greater than that of EA-IgG1, mediated mainly through Fc gamma RIII. In ADCC assays using lymphocytes (NK cells) as effector cells and papainised RBC target cells, only a minority of IgG1 anti-D Mabs were shown to be able to mediate haemolysis in the presence of monomeric IgG (AB serum or IVIg). These interactions were mediated solely through Fc gamma RIII. Haemolysis via Fc gamma RIII may depend on the presence of certain sugars on the oligosaccharide moiety of IgG. Most Mabs (IgG1, IgG2, IgG3 and IgG4) elicited intermediate, low or no haemolysis in these assays. Blocking studies indicated that low activity IgG1 and IgG4 anti-D utilised only Fc gamma RI. Other IgG1 and IgG3 Mabs appeared to promote haemolysis through Fc gamma RI and Fc gamma RIII while IgG2 was inhibited by Mabs to both Fc gamma RII and Fc gamma RIII, suggesting a variety of Fc gamma R are utilised for anti-D of low haemolytic activity. Excellent agreement between the results of the lymphocyte ADCC assays and antibody quantitation was observed between the participating laboratories.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Inmunoglobulina G/inmunología , Isoanticuerpos/inmunología , Receptores de IgG/inmunología , Anticuerpos Monoclonales/química , Citotoxicidad Celular Dependiente de Anticuerpos , Glicosilación , Hemólisis , Humanos , Inmunoglobulina G/química , Inmunoglobulinas Intravenosas/inmunología , Isoanticuerpos/química , Células Asesinas Naturales/inmunología , Mediciones Luminiscentes , Linfocitos/inmunología , Macrófagos/inmunología , Monocitos/inmunología , Oligosacáridos/inmunología , Fagocitosis , Procesamiento Proteico-Postraduccional , Estructura Terciaria de Proteína , Receptores de IgG/clasificación , Globulina Inmune rho(D)RESUMEN
Plasmin triggers a strong metabolic activation in human platelets, leading to shape change and granule exocytosis. However, its capacity to induce cell aggregation remains discussed and, when observed, this aggregation is preceded by a remarkable lag phase. We have thus investigated the effect of plasmin on the adhesive proteins which can be secreted by isolated platelets and mediate cell-to-cell interactions, but are also substrates for the enzyme. Immunoblot analysis of fibrinogen (Fg), thrombospondin-1 (TSP-1), fibronectin (Fn) and von Willebrand factor (vWf) was performed on extracts of platelets exposed under stirring to increasing concentrations of plasmin for up to 10 min at 37 degrees C. Under conditions leading to formation of large aggregates, Fg, Fn and TSP-1 are extensively degraded concomitantly with their secretion, and readily lost from the surface of aggregated cells. Part of the monomers in the platelet vWf are cleaved during secretion into two main fragments with Mr approximately 180,000 and approximately 145,000. However, multimer distribution analysis shows only a slight decrease in the very high molecular weight multimers, and most of the fragmented as well as intact vWf remains associated with the platelet surface when aggregation is maximal. That indeed vWf largely supports plasmin-induced aggregation is suggested by the observation that platelets from a patient with type 3 von Willebrand's disease, who totally lacks vWf, show little aggregation in response to the enzyme. Finally, plasmin-induced aggregation can be totally inhibited by antagonists of the alpha(IIb)beta3 integrin. The present study thus indicates a major role for secreted vWf in platelet aggregation induced by plasmin, through its likely interaction with the multifunctional receptor alpha(IIb)beta3.
Asunto(s)
Plaquetas/metabolismo , Fibrinolisina/farmacología , Agregación Plaquetaria/efectos de los fármacos , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/fisiología , Factor de von Willebrand/fisiología , Biopolímeros , Endopeptidasas/sangre , Exocitosis/efectos de los fármacos , Fibrinógeno/análisis , Fibronectinas/análisis , Humanos , Agregación Plaquetaria/fisiología , Trombospondina 1/análisis , Enfermedades de von Willebrand/sangre , Factor de von Willebrand/química , Factor de von Willebrand/metabolismoRESUMEN
von Willebrand factor antigen II (vWFAgII) is the 100 kDa propolypeptide of endothelial cell marker von Willebrand factor (vWF). Our aim was to determine the relationship between vWFAgII and mature vWF and an additional endothelial cell marker, soluble thrombomodulin, in atherosclerosis. To do this, we measured levels of all three by enzyme-linked immunosorbent assay in plasma obtained from 24 patients with peripheral vascular disease (PVD), from 25 patients who survived a myocardial infarction [i.e. had ischaemic heart disease (IHD)], and from 47 age- and sex-matched controls. We found raised levels of vWFAgII in PVD (57.3 +/- 15.3 microg/dl; mean +/- standard deviation) and in IHD (53.4 +/- 19.2 microg/dl) compared with the controls (35.7 +/- 12.0 microg/dl; analysis of variance P < 0.001). Raised levels of vWf were found in both groups of patients but raised soluble thrombomodulin was found only in patients with PVD. Levels of vWFAgII correlated with those of vWf (r = 0.45, P < 0.001) but not with soluble thrombomodulin (r = 0.14, P = 0.17), nor any of the major risk factors for atherosclerosis. Our brief study reports raised levels of vWFAgII in atherosclerosis. This may, like that of vWf, be related to endothelial cell damage, although the incomplete correlation between the two implies different metabolic and/or release mechanisms.
Asunto(s)
Antígenos/análisis , Arteriosclerosis/sangre , Trombomodulina/sangre , Factor de von Willebrand/análisis , Anciano , Arteriosclerosis/epidemiología , Biomarcadores , Comorbilidad , Femenino , Humanos , Hipertensión/epidemiología , Lípidos/sangre , Lipoproteínas/sangre , Masculino , Persona de Mediana Edad , Infarto del Miocardio/sangre , Enfermedades Vasculares Periféricas/sangre , Valor Predictivo de las Pruebas , Factores de Riesgo , Fumar/epidemiología , SolubilidadRESUMEN
Von Willebrand disease is characterised by a quantitative (type 1) or qualitative (type 2) decrease in von Willebrand factor (vWF) a multimeric glycoprotein involved in primary haemostasis. The propeptide of von Willebrand, also named vWF antigen II (vWF:AgII), is released from platelets and endothelial cells and circulates in plasma as a glycoprotein of 100 kD. In the present study, we attempted to determine whether vWF:AgII level may provide information on the synthesis of vWF, specially in patients with von Willebrand disease (vWD). To elucidate that point, we developed an ELISA and quantify the vWF:AgII in normal individuals and in various vWD patients. The propeptide molar concentration was found to be 5 nM as compared to 31 nM for mature vWF. In normal individuals, the level of vWF:AgII was significantly decreased in females from O and A blood groups. In type 2 vWD patients the level of plasma vWF:AgII appears normal in the patients with normal level of platelet vWF. In type 2 B vWD characterised by increased affinity of mature vWF for platelet glycoprotein Ib, the vWF:AgII in contrast to the vWF antigen (vWF:Ag) was not decreased. In type 2A vWD patients the level of vWF:AgII was decreased in patients with absence of high molecular weight vWF in platelets and plasma but normal in patients with increased sensitivity to proteolysis. Finally, in type 1 vWD, some studied patients have a parallel decrease in vWF:AgII and vWF:Ag whereas in others, the vWF:Ag levels were much more affected than corresponding vWF:AgII levels, as observed in some type 2 vWD patients. Thus, in contrast to that already described, the plasma vWF:AgII level cannot discriminate type 1 from type 2 vWD patients. We conclude that the vWF:AgII measurement provides additional information on the mechanisms responsible for vWD and might also contribute to the classification of vWD patients.
Asunto(s)
Antígenos/sangre , Enfermedades de von Willebrand/sangre , Factor de von Willebrand/metabolismo , Estudios de Casos y Controles , Medios de Cultivo , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Modelos Lineales , Masculino , Valores de Referencia , Enfermedades de von Willebrand/inmunología , Factor de von Willebrand/inmunologíaRESUMEN
Type 2B of von Willebrand disease (vWD) refers to qualitative variants with increased affinity of von Willebrand factor (vWF) for platelet glycoprotein Ib (GPIb). All the mutations responsible for type 2B vWD have been located in the A1 domain of vWF. In this study, various recombinant von Willebrand factors (rvWF) reproducing four type 2B vWD missense mutations were compared to wild-type rvWF (WT-rvWF) for their spontaneous binding to platelets and their capacity to induce platelet activation and aggregation. Our data show that the multimeric pattern of each mutated rvWF is similar to that of WT-rvWF but the extent of spontaneous binding and the capacity to induce platelet activation and aggregation are more important for the R543Q and V553M mutations than for the L697V and A698V mutations. Both the binding of mutated rvWFs to platelets and platelet aggregation induced by type 2B rvWFs are inhibited by monoclonal anti-GPIb and anti-vWF antibodies, inhibitors of vWF binding to platelets in the presence of ristocetin, as well as by aurin tricarboxylic acid. On the other hand, EDTA and a monoclonal antibody directed against GPIIb/IIIa only inhibit platelet aggregation. Furthermore, the incubation of type 2B rvWFs with platelets, under stirring conditions, results in the decrease in high molecular weight vWF multimers in solution, the extent of which appears correlated with that of plasma vWF from type 2B vWD patients harboring the corresponding missense mutation. This study supports that the binding of different mutated type 2B vWFs onto platelet GPIb induces various degrees of platelet activation and aggregation and thus suggests that the phenotypic heterogeneity of type 2B vWD may be related to the nature and/or location of the causative point mutation.
Asunto(s)
Mutagénesis Sitio-Dirigida , Activación Plaquetaria , Agregación Plaquetaria , Enfermedades de von Willebrand/genética , Factor de von Willebrand/farmacología , Fibrinógeno/fisiología , Humanos , Modelos Lineales , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/fisiología , Complejo GPIb-IX de Glicoproteína Plaquetaria/fisiología , Unión Proteica , Proteínas Recombinantes/farmacología , Valores de Referencia , Enfermedades de von Willebrand/sangre , Factor de von Willebrand/metabolismoRESUMEN
Quantitative or qualitative assay of platelet von Willebrand factor (vWF) is required for the classification of patients suffering from von Willebrand disease (vWD). The major interest of this classification is the administration of specific and appropriate treatment to each category of vWD patients. However, because platelet lysate is prepared from washed platelets, the analysis of platelet vWF is not performed in routine. To overcome this problem, platelet lysates were prepared either with a new method which does not require washing procedure or with the established protocol, then respective platelet vWF characteristics were compared. Our data show that the two methods provide comparable information required for the characterization of types 1 and 2 vWD patients. With this new procedure, complete phenotypic data including the characteristics of platelet vWF can be obtained from most of the vWD patients.
Asunto(s)
Plaquetas/química , Separación Celular/métodos , Enfermedades de von Willebrand/sangre , Factor de von Willebrand/análisis , Conservación de la Sangre , Centrifugación , Gránulos Citoplasmáticos/química , Detergentes , Ensayo de Inmunoadsorción Enzimática , Humanos , Peso Molecular , Octoxinol , Fenotipo , Enfermedades de von Willebrand/clasificaciónRESUMEN
We report the results of an immunogold electron microscopical analysis on microfibrils from the arterial subendothelium showing that thrombospondin (TSP) is present on 40 nm-diameter structures joining 8-10 nm-diameter microfibrils containing fibrillin. They differ from type VI collagen which forms 3-5 nm-diameter microfibrils. TSP containing microfibrils (TSP-MF) extracted from human umbilical arteries did not contain fibrillin or type VI collagen. Blood platelet interactions with TSP-MF were not modified by anti-fibrillin or anti-type VI collagen antibodies. In situ, vWF was bound to cross-linked microfibrils, at the level of their 40 nm junction, and a double-labeling with the anti-thrombospondin and anti-vWF antibodies was observed. In vitro, vWF binding to TSP-MF was not inhibited by anti-fibrillin or anti-type VI collagen antibodies. These results suggest a structural and functional heterogeneity of microfibrils and emphasize the role of TSP-MF in the thrombogenicity of the subendothelium.
Asunto(s)
Endotelio Vascular/inmunología , Glicoproteínas de Membrana/inmunología , Proteínas de Microfilamentos/metabolismo , Colágeno/inmunología , Proteínas de la Matriz Extracelular , Fibrilinas , Humanos , Técnicas In Vitro , Proteínas de Microfilamentos/inmunología , Microscopía Inmunoelectrónica , Agregación Plaquetaria , Trombospondinas , Factor de von Willebrand/inmunologíaRESUMEN
Von Willebrand disease (vWD) results from quantitative (types 1 and 3) or qualitative (type 2) deficiency of von Willebrand factor (vWF). This glycoprotein present in plasma is involved in platelet adhesion at the site of vascular injury and serves as the carrier of antihaemophilic A factor (FVIII). Whereas recent studies have identified mutations in patients suffering from type 2 vWD, the integrity of the carbohydrate moiety of vWF in these patients is still matter of debate. In order to analyse in the plasma milieu the carbohydrate content of plasma vWF from various well-characterized type 2 vWD patients, we developed a colorimetric assay in microtiter plate based on the use of peroxidase-conjugated lectins specific for either alpha 2-6 sialic acid or beta 1-4 galactose. Removal of sialic acid from purified plasma vWF induced significant changes in the reactivity of both lectins. The analysis of various normal plasmas showed no influence of the blood groups and allowed us to compare various vWD patients. The reactivity of lectins for plasma vWFs from two type 2A and six type 2B vWD patients harbouring different mutations was not statistically different from that of a pool of normal plasmas. We conclude that the alpha 2-6 sialic acid and beta 1-4 galactose content of plasma vWF is not altered in these patients affected with types 2A and 2B vWD.
Asunto(s)
Carbohidratos/análisis , Enfermedades de von Willebrand/sangre , Factor de von Willebrand/análisis , Colorimetría/métodos , Humanos , Mutación Puntual , Enfermedades de von Willebrand/genética , Factor de von Willebrand/química , Factor de von Willebrand/genéticaRESUMEN
Type 2A of von Willebrand disease refers to qualitative variants with decreased platelet dependent function that is associated with the absence of high molecular weight forms of von Willebrand factor (vWF) multimers. Type 2B refers to qualitative variants with increased affinity for platelet glycoprotein Ib. In this report we describe the study of a patient who has been previously diagnosed as having subtype 2A von Willebrand disease (vWD), because she had no heightened ristocetin-induced platelet aggregation, no large and intermediate molecular weight von Willebrand factor (vWF) multimers in plasma, and no increase in plasma vWF capacity to bind to normal platelets in the presence of low ristocetin concentrations. The DNA sequencing of the 3' part of the exon 28 of the vWF gene where most of the subtype 2A mutations have already been identified, did not detect any nucleotide change. At variance, a G to A transition changing the encoded amino acid residue from Val 553 to Met in mature vWF, was found in the 5' part of this exon. This mutation which has already been found in several unrelated families with 2B vWD and the increased binding of the patient platelet vWF on normal platelets in the presence of low ristocetin concentrations provide evidence for subtype 2B vWD. This study thus illustrates the importance of the molecular characterization of patients in the correct diagnosis and classification of type 2 vWD.
Asunto(s)
Enfermedades de von Willebrand/sangre , Enfermedades de von Willebrand/diagnóstico , Factor de von Willebrand/genética , Secuencia de Bases , Datos de Secuencia Molecular , Peso Molecular , Agregación Plaquetaria/genética , Mutación Puntual , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Enfermedades de von Willebrand/genética , Factor de von Willebrand/químicaRESUMEN
Type IIB von Willebrand disease is characterized by the selective loss of high molecular weight von Willebrand factor (vWF) multimers from plasma and enhanced platelet agglutination of platelet-rich-plasma in the presence of low concentrations of ristocetin. We identified, in two related patients, a C-->G transversion resulting in the substitution of Valine for Leucine at position 697 of the mature subunit of vWF. We reproduced this mutation in vWF cDNA and expressed the recombinant protein in Cos-7 cells. The subunit composition and multimeric structure of mutated protein (rvWFLeu697Val) were similar to the wild-type recombinant (WTrvWF). Ristocetin-induced binding of rvWFLeu697Val to platelets was markedly increased in the presence of low doses of ristocetin and slightly increased with botrocetin as compared with that for WTrvWF, whereas collagen binding was not affected by the mutation. These data show that the Leu 697-->Val substitution is not a rare polymorphism but is responsible for the subtype IIB characteristic abnormalities identified in the two affected patients; however, it is not located in the area of vWF (amino acid 540 to amino acid 578) where most of the other type IIB mutations have already been reported.
Asunto(s)
Mutación , Enfermedades de von Willebrand/etiología , Factor de von Willebrand/genética , Anciano , Secuencia de Bases , Plaquetas/metabolismo , Venenos de Crotálidos/farmacología , Femenino , Humanos , Datos de Secuencia Molecular , Fenotipo , Ristocetina/farmacología , Factor de von Willebrand/metabolismoRESUMEN
Understanding the effect of fibrinolysis on platelet function is of clinical importance. Plasmin is recognized to affect platelet adhesive function by reducing the interaction of platelet glycoprotein (GP) Ib with von Willebrand factor (vWF) bound to the subendothelium. This platelet function is commonly explored in vitro by the ristocetin-induced agglutination test. Our previous study demonstrated a plasmin-induced redistribution of GP Ib molecules from the platelet surface to the linings of the surface-connected canalicular system (SCCS), a critical mechanism for understanding plasmin-induced GP Ib dysfunction. Here, we demonstrate that neutralization of plasmin by its inhibitors, aprotinin or tripeptide Val-Phe-Lys-CH2Cl, permits a time dependent recovery (within 30 min) of ristocetin-induced agglutination in the platelets which were stimulated by plasmin at < 1 CU ml-1. This functional recovery was accompanied with a restoration of a normal amount of GP Ib on the platelet surface, as measured by the binding of both monoclonal anti-GP Ib antibody SZ 2 and 125I-labelled vWF to the platelets. Cytochalasin D did not inhibit this recovery, suggesting that this process may be due to passive actin depolymerization. These findings were further confirmed by immunoelectron microscopic study. Utilizing the platelets pre-labelled with anti-GP Ib antibody prior to plasmin stimulation, it was demonstrated that the observed recovery is due to a reverse translocation from the SCCS to the plasma membrane of the same GP Ib molecules which were present initially at the cell surface.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Plaquetas/metabolismo , Fibrinolisina/farmacología , Glicoproteínas de Membrana Plaquetaria/metabolismo , Aglutinación , Anticuerpos Monoclonales/inmunología , Aprotinina/farmacología , Transporte Biológico , Humanos , Microscopía Inmunoelectrónica , Ristocetina/antagonistas & inhibidores , Ristocetina/farmacología , Factor de von Willebrand/metabolismoRESUMEN
Thrombin induces a redistribution of glycoprotein (GP) Ib/GP IX complex from the platelet surface into the surface connected canalicular system (SCCS). This redistribution results in a reduced interaction of platelet GP Ib with von Willebrand factor (vWF) bound to subendothelium leading to impaired platelet adhesion. In this study we show that the platelet aggregation and degranulation require concentrations of thrombin above 0.05 U/ml, while the decrease in GP Ib function (about 50% of control value), as determined by ristocetin induced platelet agglutination, can be induced by lower concentrations (0.01-0.04 U/ml). Moreover, we show that when adding thrombin inhibitors to the platelets preincubated with < 0.04 U/ml thrombin for 5 min, their agglutinability by ristocetin was gradually recovered within 30 min, indicating that in these conditions the decrease in platelet adhesiveness is reversible. Immuno-electromicroscopic study showed that this restoration of platelet GP Ib function was associated with a reversed translocation of GP Ib from the SCCS to the plasma membrane. The data obtained from counting gold particles showed that the ratio of GP Ib immunolabelling on the external membrane versus that on the SCCS was 3.31 +/- 0.90 for resting platelets, down-regulated to 0.84 +/- 0.13 (P < 0.05 versus resting platelets) for the platelets treated with 0.04 U/ml thrombin and returned to 2.63 +/- 2.21 (P > 0.05 versus resting platelets) after incubation for 30 min with hirudin. However, the translocation of GP Ib was poorly reversed by thrombin inhibitors when higher concentrations of thrombin were used which induced platelet aggregation and large extent of degranulation. We conclude that thrombin affects platelets in a dose dependent manner, and that at low concentrations the decrease in platelet GP Ib related function is a reversible phenomenon.
Asunto(s)
Plaquetas/efectos de los fármacos , Glicoproteínas de Membrana Plaquetaria/efectos de los fármacos , Trombina/farmacología , Antitrombinas/farmacología , Plaquetas/metabolismo , Plaquetas/ultraestructura , Células Cultivadas , Relación Dosis-Respuesta a Droga , Hemaglutinación/efectos de los fármacos , Humanos , Microscopía Inmunoelectrónica , Agregación Plaquetaria/efectos de los fármacos , Ristocetina/antagonistas & inhibidores , Ristocetina/farmacología , Factor de von Willebrand/metabolismoRESUMEN
We developed a simple and fast method for studying the heparin binding of von Willebrand factor (vWF) in the plasma milieu. Using plasma from patients with von Willebrand disease (vWD) subtype II, we found that the heparin binding was impaired when compared with a normal plasma control. Further experiments performed with purified vWF of various multimeric composition, obtained either by gradual reduction or gel filtration, confirmed that heparin binding is dependent on the multimerization of vWF and that high molecular weight (HMW) multimers of vWF are required for normal heparin binding. After reduction of plasma vWF by 1.5 mM DTT, the vWF monomer still binds to heparin but to a lower extent. Under these conditions, no significant differences were obtained between control and patients showing that the heparin binding domain located on the vWF subunit is not altered in the subtypes IIA, IIB and IIC studied.
Asunto(s)
Heparina/metabolismo , Conformación Proteica , Factor de von Willebrand/metabolismo , Anticuerpos Monoclonales/inmunología , Sitios de Unión , Cromatografía de Afinidad , Cromatografía en Gel , Electroforesis en Gel de Agar , Humanos , Plasma , Unión Proteica , Sensibilidad y Especificidad , Sefarosa/análogos & derivados , Enfermedades de von Willebrand/sangre , Enfermedades de von Willebrand/clasificación , Factor de von Willebrand/química , Factor de von Willebrand/inmunologíaRESUMEN
A very highly purified von Willebrand factor (vWF) concentrate was analyzed in order to evaluate its suitability for the treatment of von Willebrand's disease (vWD). The functional activity of vWF assessed by its ristocetin cofactor activity (vWF:RCo) correlated with the level of vWF antigen (vWF:Ag), with the vWF:RCo/vWF:Ag ratios ranging from 0.56 to 1.02, and the specific activity being always greater than 50 IU vWF:RCo/mg protein. Electrophoretic analysis showed a normal pattern of high, intermediate and low-molecular-weight multimers of vWF. The biological activity of vWF was also evaluated by studying its ability to bind to collagen and to platelet receptors in the presence of either ristocetin or thrombin. Furthermore, these functional activities of vWF were confirmed by the capacity of this concentrate to induce platelet adhesion to collagen in a perfusion system. Moreover, the vWF present in this preparation was able to bind factor VIII. All these in vitro data suggest that this preparation is likely to be effective in the treatment of vWD patients.
Asunto(s)
Factor de von Willebrand/normas , Detergentes/farmacología , Estudios de Evaluación como Asunto , Hemostasis/fisiología , Humanos , Métodos , Solubilidad , Solventes/farmacología , Equivalencia Terapéutica , Enfermedades de von Willebrand/tratamiento farmacológico , Factor de von Willebrand/farmacocinética , Factor de von Willebrand/uso terapéuticoRESUMEN
The terms glycoprotein IV (GPIV) and glycoprotein IIIb (GPIIIb) have been used interchangeably and reports in the literature have indicated this glycoprotein as having a molecular weight variously described as either 88,000 or 97,000, a fast anodal mobility on crossed electrophoresis and either 13 or less than 1 methionine residues on amino acid analysis of the purified glycoprotein. To resolve these discrepancies, we have evaluated the characteristics of GPIV both in whole platelets and after isolation. These studies have shown that the term GPIV defines a protease-resistant platelet surface glycoprotein with Mr 88,330 +/- 2,240 which is immunologically identical with the CD36 differentiation antigen, which migrates with a relatively slow anodal mobility on crossed immunoelectrophoresis and which contains approximately 13 methionine residues per mole.
Asunto(s)
Antígenos de Diferenciación/análisis , Glicoproteínas de Membrana Plaquetaria/análisis , Animales , Antígenos CD/análisis , Antígenos de Diferenciación/aislamiento & purificación , Antígenos CD36 , Inmunoelectroforesis Bidimensional , Lectinas , Glicoproteínas de Membrana Plaquetaria/aislamiento & purificación , Pruebas de Precipitina , ConejosRESUMEN
A factor VIII (FVIII) concentrate, virus-inactivated by the solvent/detergent procedure, was studied in vitro. In contrast with most high-purity, virus-inactivated FVIII concentrates, it contains not only high levels of von Willebrand factor (vWF) antigen and ristocetin cofactor activity but also high molecular weight forms of von Willebrand factor. Furthermore, it is able to promote platelet adhesion on collagen in a perfusion system. In vivo studies performed in patients with different types of von Willebrand's disease provided evidence that this concentrate corrects Duke's bleeding time and prevents or stops haemorrhages. Thus, the particular advantages of this FVIII/vWF preparation are safety, low content of contamination proteins, and efficacy in von Willebrand's disease.
Asunto(s)
Contaminación de Medicamentos/prevención & control , Factor VIII/uso terapéutico , Enfermedades de von Willebrand/tratamiento farmacológico , Antígenos/análisis , Tiempo de Sangría , Detergentes , Factor VIII/aislamiento & purificación , Factor VIII/farmacología , Humanos , Peso Molecular , Adhesividad Plaquetaria/efectos de los fármacos , Ristocetina/análisis , Ristocetina/sangre , Solventes , Virus , Enfermedades de von Willebrand/sangre , Factor de von Willebrand/análisis , Factor de von Willebrand/inmunologíaRESUMEN
In this cooperative study, we explored the role of the carbohydrate moiety (CHO) of von Willebrand factor (vWF) in supporting platelet adhesion. Because of previous discrepant results, all purification steps and CHO modifications by various enzymes were critically evaluated. Under our conditions, CHO-modified vWF preparations contained less than 5% of the initial sialic acid ([Neu]-ase-vWF) and less than 45% ([Neu-Gal]-ase-vWF) or 21% ([Neu-Gal-eF]-ase-vWF) of the D-galactose. These preparations usually showed increased electrophoretic mobility but no significant loss of high-mol-wt multimers when proteolysis had been prevented. Some degree of proteolysis was noted in some carbohydrate-modified vWFs, but the degree of degradation observed did not correlate with the removal of D-galactose. Platelet adhesion to various matrices increased after removal of the terminal sialic acid ([Neu]-ase-vWF) and approximately 45% of the D-galactose ([Neu-Gal]-ase-vWF), but returned to normal values when greater than 70% of the total carbohydrate had been removed by endoglycosidase F [Neu-Gal-ef]-ase-vWF). These changes in reactivity were also reflected in the spontaneous aggregation in normal platelet-rich plasma (PRP) after CHO removal.
Asunto(s)
Conformación de Carbohidratos , Adhesividad Plaquetaria , Ácidos Siálicos/sangre , Factor de von Willebrand/fisiología , Electroforesis en Gel de Poliacrilamida , Galactosa/metabolismo , Glicósido Hidrolasas , Humanos , Manosil-Glicoproteína Endo-beta-N-Acetilglucosaminidasa , Ácido N-Acetilneuramínico , Neuraminidasa , Agregación Plaquetaria , Relación Estructura-Actividad , Factor de von Willebrand/aislamiento & purificaciónRESUMEN
We studied a murine monoclonal antibody (211 A6) to von Willebrand factor (vWF) with a view to investigating structure-relationship of plasma vWF. The specificity of this antibody has been substantiated by ELISA tests and indirect immunofluorescence. It reacts with purified vWF, normal plasma but not with plasma or platelets from a severe von Willebrand's disease patient. Monoclonal antibody 211 A6 is a potent inhibitor of ristocetin-induced platelet aggregation. The 125I-FVIII/vWF binding to platelets in presence of ristocetin is totally inhibited by low 211 A6 concentrations. Thrombin-induced binding of vWF to platelets is not affected by 211 A6. The ability of this antibody to inhibit platelet adhesion to subendothelium and to collagen was investigated with a perfusion model. The complete inhibition of platelet adhesion by 211 A6 questions the similarity or the interrelationship in vWF domains involved in ristocetin-induced platelet functions and platelet adhesion.